small cap stocks
A 30-Year-Old Copper Target Finally Gets Drilled, Plus a Lithium Explorer’s Exit Into Gold
A copper target in British Columbia hadn’t seen a meaningful drill in three decades until this week. A lithium exploration company decided it no longer wants to be a lithium exploration company, and is buying a gold royalty instead. A healthcare marketplace signed a partnership with no agreed revenue split yet, then got approved to…
Gold Miners Post Their Best Month Ever. Juggernaut Exploration Confirms a 600-Meter Gold Zone. Bitcoin Clears $80,000.
Gold miners just had their best month on record, gaining more than chip stocks managed even at their hottest. A driller in British Columbia’s Golden Triangle confirmed a new mineralized zone extends 600 meters along strike and 580 meters deep, with assays still to come. Bitcoin cleared $80,000 for the first time in three months,…
A Rare Earth Rally, an MS Drug Trial Clearance, and Bitcoin Above $77,000
The market took two weeks to notice a rare earth resource update, then made up for lost time all at once. A multiple sclerosis drug cleared the FDA for human trials after spending the spring on clinical hold. Bitcoin climbed above $77,000 and pulled a handful of large, US-listed crypto names along with it, though…
Good Data, Bad Reaction: NeOnc Technologies This Week, Plus FOBI AI’s Return From a Trading Halt
A brain cancer drug beat its historical benchmark by nearly two and a half times, with a p-value most drugs never see, and the stock popped 19% before the open and closed down anyway on 20 times normal volume. A company that had been frozen out of trading for a missed filing came back to…
Creative Medical Technology Surges 100% on Patent News, Plus a Reverse Merger and a Record Week for Gold Stocks
A patent that hasn’t even issued yet sent a thinly traded diabetes stock up 100% in a single session on 25 times its normal volume. A Utah AV equipment maker filed routine merger paperwork and jumped 98% after hours, even though the deal leaves its own shareholders with barely a tenth of the combined company.…
Outlook Therapeutics Wins FDA Approval, Plus a Copper Strike and a Crypto Lending Launch
Bevacizumab has quietly treated wet macular degeneration off-label for two decades, cheap and effective but never actually built or labeled for the eye. Outlook Therapeutics spent years and two rejected applications trying to close that gap. The FDA signed off on Friday. In Chile a driller pulled 111.9 meters of 0.97% copper out of ground…







